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Abstract
Background: Parkinson’s disease (PD) is characterized by selective degeneration of dopaminergic (DA) neurons of
the substantia nigra pars compacta (SN) while neighboring ventral tegmental area (VTA) DA neurons are relatively
spared. Mechanisms underlying the selective protection of the VTA and susceptibility of the SN are still mostly
unknown. Here, we demonstrate the importance of balance between astrocytes and microglia in the susceptibility
of SN DA neurons to the PD mimetic toxin 1-methyl-4-phenylpyridinium (MPP+).
Methods: Previously established methods were used to isolate astrocytes and microglia from the cortex (CTX), SN,
and VTA, as well as embryonic midbrain DA neurons from the SN and VTA. The transcriptional profile of isolated
microglia was examined for 21 canonical pro- and anti-inflammatory cytokines by qRT-PCR with and without MPP+
exposure. Homo- and heterotypic co-cultures of neurons and astrocytes were established, and the effect of altering
the ratio of astrocytes and microglia in vitro on the susceptibility of midbrain DA neurons to the PD mimetic toxin
MPP+ was investigated.
Results: We found that regionally isolated microglia (SN, VTA, CTX) exhibit basal differences in their cytokine
profiles and that activation of these microglia with MPP+ results in differential cytokine upregulation. The addition
of microglia to cultures of SN neurons and astrocytes was not sufficient to cause neurodegeneration; however,
when challenged with MPP+, all regionally isolated microglia resulted in exacerbation of MPP+ toxicity which was
alleviated by inhibition of microglial activation. Furthermore, we demonstrated that isolated VTA, but not SN,
astrocytes were able to mediate protection of both SN and VTA DA neurons even in the presence of exacerbatory
microglia; however, this protection could be reversed by increasing the numbers of microglia present.
Conclusion: These results suggest that the balance of astrocytes and microglia within the midbrain is a key factor
underlying the selective vulnerability of SN DA neurons seen in PD pathogenesis and that VTA astrocytes mediate
protection of DA neurons which can be countered by greater numbers of deleterious microglia.
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Background
Parkinson’s disease (PD) is a progressive neurodegenerative disease which is characterized by the selective degeneration of dopaminergic (DA) neurons of the substantia
nigra pars compacta (SN), whereas the neighboring DA
neurons of the ventral tegmental area (VTA) are relatively
spared [1]. Previous studies have examined the DA neurons of these two regions to better understand why only
one subset of DA neurons is significantly more vulnerable
to PD than the other [2–5]. Recently, greater focus has
been placed on extrinsic mechanisms, such as the role of
astrocytes, in the disease process suggesting that neuronal
vulnerability results from both intrinsic and extrinsic influences. Indeed, our recent work (Kostuk et al. 2018, in
submission) has demonstrated a vast transcriptional difference between SN and VTA astrocytes such that VTA, but
not SN, astrocytes release factors which mediate protection of VTA, SN, and induced pluripotent stem cell (iPSC)
DA neurons. In addition to astrocytes, the role of microglia, another important glial cell type, in the pathogenesis
of PD has become an area of great interest.
Microglia are considered to be the innate immune
cells of the brain [6]. Their role in the clearance of damaged cells, such as neurons, and other foreign contaminants of the brain is well established [7–9]. It is well
known that microglia derive from a myeloid lineage [10]
and that injury or disease can cause increased microglial
activation within the brain [11–14]. Indeed, in PD
patients and animal models of PD, greater numbers of
microglia [15], as well as enhanced microglial reactivity
[16, 17], are observed in the SN. In addition to their role
as scavengers in the brain, microglia also release proand anti-inflammatory molecules in response to insult
or injury [9, 18, 19]. Indeed, the canonical microglial activator lipopolysaccharide (LPS) has been used to stimulate microglial activation and the subsequent cytokine
release in order to model the immune response in vivo
and in vitro [12, 20–22]. Thus, it has been reported that
LPS stimulation of microglia within the SN is sufficient
to produce DA neurodegeneration [23], suggesting a role
for microglia and their factors in disease progression.
Previous studies have additionally examined the interaction of microglia with PD mimetic toxins. For example,
rotenone, a pesticide known to be a DA neurotoxin, was
shown to require the presence of microglia in order to
mediate toxicity of midbrain DA neurons in culture [24].
This raises the possibility that the interaction of PD mimetic toxins with microglia could be a potential pathway
by which neurodegeneration occurs. In addition to the
potential role that toxins could have on microglia, leading
to an exacerbation of toxicity, the ratio of microglia to
neurons within the brain could potentially produce different reactions to inflammatory stimuli. Previous work has
shown that the regional distribution of microglia
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throughout the brain is diverse [25, 26], with the SN being
populated by a high ratio of microglia to neurons. Furthermore, recent transcriptional profiling of discrete brain
regions (cortex, hippocampus, cerebellum, striatum) has
suggested that similar to astrocytes, microglia exhibit
regionally distinct transcriptional profiles [27]. However,
the potential regionality of midbrain microglia has yet to
be investigated.
Therefore, in this study, we sought to determine
whether midbrain SN and VTA microglia exhibit regionally specific gene expression profiles and whether these
regionally isolated microglia can contribute differentially
to the susceptibility of SN DA neurons to MPP+induced toxicity as compared to the VTA. Furthermore,
we investigated whether the ratio of microglia to
neurons to astrocytes within the midbrain plays a role in
the selective vulnerability of the SN to PD mimetic
toxins. We found that regionally isolated microglia from
three distinct brain regions, the cortex, SN, VTA, exhibit
differential basal cytokine profiles. Furthermore, when
challenged with the PD mimetic toxin MPP+, all
regionally isolated microglia respond with distinct
cytokine profiles. Interestingly, the addition of microglia
alone is not sufficient to induce DA neuron death in
cultures of either SN or VTA neurons. However, when
challenged with MPP+, all regionally isolated microglia
similarly exacerbate MPP+ toxicity, and this exacerbation
of toxicity can be alleviated by inhibiting the activation of
microglia via pharmacological inhibition of the TLR4
receptor. Finally, we demonstrated that greater ratios of
VTA, but not SN, astrocytes are able to protect both SN
and VTA DA neurons from MPP+ toxicity and that
increasing the microglial ratio counters the protective
effect of VTA astrocytes. Together, these results suggest
that the susceptibility of SN DA neurons to a PD mimetic
toxin results from a regional sensitivity to multiple
environmental factors, rather than simply from an
intrinsic neuronal vulnerability. A greater appreciation of
the role of extrinsic mechanisms, mainly the protective
nature of astrocytes and deleterious functions of
microglia, in disease pathogenesis is important for the
consideration of possible therapeutics in PD.

Methods
Animals and IACUC policies

All animals used in this study were maintained in
accordance with the Office of Animal Resources at Thomas
Jefferson University. The protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) at
Thomas Jefferson University, protocol #457K/01499.
Embryonic tissue culture

Timed pregnancies were performed using male and female rats from our colony of animals expressing green
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fluorescent protein under control of the human tyrosine
hydroxylase promotor (TH-GFP) [1]. Embryonic day
zero (E0) was determined as the first day a vaginal plug
was visible. On E14.5, embryos were harvested and
placed in ice cold DPBS (Gibco #14190-144; no CaCl2
or MgCl2). GFP+ pups were visualized under a dissection microscope (Nikon SMZ1500; adjustable × 1–× 11.5
objective) by using a high-pressure mercury lamp with a
495-nm filter attachment. The midbrain was surgically
extracted and cleaned of non-GFP+ tissues, and the
VTA and SN were carefully separated. Tissues were
collected and placed in 2.5 mL of enzymatic dissociation solution containing 5 mg DNAse I (Sigma
#10104159001), 5 mg Papain (Sigma #10108014001),
and 50 mg L-cysteine (Sigma) for up to 30 min. Solution
was gently agitated every 5 min to aid in dissociation. NEP
basal media (DMEM/F12, B-27 and N2 Supplements
(Gibco), 1 mg/mL BSA, and Penn/Strep) was added to terminate the enzymatic reaction. Tissues were then briefly
spun at 1000 rpm for 2 min, and the supernatant media
was aspirated. Tissues were re-suspended in culture media
(NEP basal media + 5% FBS) for 5 min prior to mechanical
dissociation. For mechanical dissociation, a 1-mL pippetor
was used with low retention tips and tissues were gently
triturated eight to ten times. Cells were then pelleted for
5 min at 1000 rpm, re-suspended in culture media, and
counted on an automated hemocytometer (Countess FLII
Invitrogen). Cells were plated in a microdrop on 96-well
tissue culture plates or 8-well chamber slides pre-coated
with poly-D-lysine (0.5 mg/mL, overnight at 37 °C) at a
density of 5–7 × 104 cells in approximately 20 μL of
culture media. Cells were allowed to attach to the
substrate before media was added to final volume of 100–
200 μL per well. Cells were allowed to mature for 6 days
prior to the addition of isolated microglia (see below) in a
1:1 microglia to neuron ratio and allowed to mature for
24 h prior to MPP+ treatment. This ratio was established
based on previous studies demonstrating similar numbers
of MAC1+ or Iba1+ microglia and TH+ neurons within
the SN [16, 28]. Experiments where inhibition of
microglia was performed utilized the commercially
available TLR4 antagonist 2-acetamidopyranoside (TLR4IN-C34, Sigma Cat# SML0832). On day 7 in vitro (DIV7),
C34 was added to cultures 2 h prior to MPP+ addition.
Cultures were fixed 24–48 h after MPP+ treatment, and
the full well was imaged using a Nikon Eclipse TI-e fitted
with a Photometrics Coolsnap ES2 camera. Images were
analyzed in ImageJ using a custom-designed macro for cell
quantification. TH-GFP+ cell counts were compared to
appropriate non-treated controls.
Tissue culture—isolated astrocytes and microglia

Astrocytes and microglia were collected using previously
published methods [2–4]. Briefly, postnatal day 1–5 GFP+
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pups were anesthetized on ice and quickly decapitated.
Brains were removed and placed in ice cold DPBS (Gibco).
GFP+ brains were visualized under a dissection microscope (Nikon SMZ1500). The midbrain and cortices were
carefully dissected away from other brain regions and
non-GFP+ tissues of the midbrain were cut away. The SN
and VTA regions were carefully separated and collected in
ice cold PBS. Whole cortices were collected and dissected
into smaller pieces prior to enzymatic digestion. Tissues
were then subjected to enzymatic digestion using a trypsin
(0.1%)/DNAse I (0.5 mg/mL) mixture for 5 min at 37 °C.
The supernatant enzyme was aspirated carefully, and
tissues were washed twice in DPBS. Tissues were then
mechanically dissociated in 0.5 mg/mL DNAse I and
gently triturated eight to ten times. Cells were then
pelleted for 5 min at 1000 rpm, re-suspended in
astrocyte media (DMEM/F12 + 10% FBS and Penn/
Strep) and plated on tissue culture flasks. Cultures
were maintained for 2–4 weeks with media changes
every other day. To separate astrocytes (adherent) and
microglia (non-adherent) for experimental use, flasks were
shaken at 220 RPM for 24 h and the non-adherent
cells collected. The cell suspension was passed
through a 70-mm cell strainer prior to centrifugation
at 1000 rpm for 5 min. The cells were re-suspended
in culture media for experimental use. Samples of
non-adherent cells were stained for the microglial
markers Iba1 (allograft inflammatory factor 1 (Iba1,
Wako #019-19741, RRID:AB_2665520) and CD11b
(BD Biosciences Cat# 550299, RRID:AB_393594) to
confirm homogeneity of the culture.
Co-culture studies: astrocyte to neuron to microglia

Neuron-astrocyte co-cultures were prepared similarly to
previously published methods [5]. Briefly, isolated regional astrocytes were trypsinized, dissociated to a single
cell suspension, and quantified. Increasing numbers of
astrocytes (60,000–120,000) were plated onto 48-well
tissue culture plates. Cells were allowed to adhere and
grow for 48 h prior to further experimentation. Subsequently, embryonic neuron preparations were carried
out to obtain TH-GFP+ neurons. Neurons were plated
onto regional astrocytes in a homo- and heterotypic
manner at 2:1 and 4:1 (astrocyte to neuron) ratios. These
ratios were established based on previous studies examining the number of astrocytes in the midbrain [28, 29],
as well as our previous work demonstrating increased
ratios of VTA but not SN astrocytes mediate protection
from MPP+ toxicity (Kostuk et al. 2018, in submission).
Twenty-four hours after plating, all cultures were treated
with 1 μM AraC to halt astrocytic proliferation. Cultures
were then allowed to mature for five more days in vitro
prior to microglial addition. Isolation and collection of
SN and VTA microglia in sufficient numbers for
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experimental manipulation would require a vast number
of animals to be sacrificed; as such, cortical microglia
were used as they were easier to obtain in sufficient
numbers. Microglia were added in a 1:1 and 2:1 (microglia to neuron) ratio. Twenty-four hours after microglial
addition, MPP+ was added at 50 μM for 24–48 h. After
MPP+ treatment, all cells were fixed and GFP+ cells
were quantified using the Nikon Eclipse camera system
described above.
RNA isolation and cDNA synthesis

Total RNA was isolated directly from freshly collected
cells in TRIzol (Invitrogen), a modification of the
guanidine isothiocyanate-phenol-chloroform extraction
method. cDNA was synthesized by using at least 1 μg
total RNA in a 20-μl reaction with Superscript IV
(Invitrogen) and oligo (dT)12–18 (Invitrogen). One
microliter of RNase H (Invitrogen) was added to each
reaction tube, and the tubes were incubated for 20 min
at 37 °C before proceeding to real-time PCR.
Real-time PCR analysis

Real-time PCR was carried out on the 7500 Real Time
PCR System using SYBR green PCR master mix (both
from Applied Biosystems). GAPDH was used as an internal control. PCR analyses were conducted in triplicate
for each sample. The reaction mix consisted of 6.35 ng
cDNA, 0.5 μM forward and reverse primer mix, and × 1
SYBR green PCR master mix. Reactions were run according to manufacturer protocols for at least 40 cycles.
Data were analyzed using the ratiometric ΔΔCT method,
and the mean relative mRNA expression for each sample
was reported. All primer sequences used can be found in
Additional file 1: Table S1.
Experimental design and statistical analysis

All data are presented as the mean ± SEM. GraphPad
was used for all statistical analysis. The statistical significance of the mean difference was calculated using a
repeated measures ANOVA with appropriate post hoc
analysis of significance. A p value < 0.05 was considered
significant.

Results
Microglia exhibit regionally specific basal cytokine profiles

To examine the potential regionality of microglia within
the midbrain, we isolated microglia from SN and VTA
and compared them to microglia from cortex (CTX)
using postnatal day 1–5 transgenic rats. Microglial purity
was estimated at 95–100% as the vast majority of cells
stained for the microglial markers Iba1 (Fig. 1a) and
CD11b (Fig. 1b). Regionally isolated microglia were then
collected and examined for their basal cytokine profile.
We found that regionally isolated microglia exhibit
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subtle differences in cytokine expression profiles (Fig. 1c,
d). In comparison to isolated CTX microglia (Fig. 1c, left
column), SN microglia exhibit greater levels of the proinflammatory cytokines IL3, CCL3, and CCL4, while
exhibiting diminished expression of IFNγ. VTA microglia
(Fig. 1c, right column) conversely express greater levels of
pro-inflammatory RANTES, Cxcl12, and CCL19, with
decreased expression of IL10. An additional comparison
was performed with CTX and SN microglia against isolated VTA microglia (Fig. 1d). We found that both SN and
CTX have greatly upregulated levels of IL10 and diminished expression of CCL19 (Fig. 1d). Together, these
results demonstrate a diverse regionality to microglia of
the midbrain based on their baseline cytokine expression
levels.
Isolated microglia have differential cytokine responses to
PD mimetic toxin MPP+

Previous studies have demonstrated that in vivo treatment with the PD toxin MPTP causes microglial activation [16, 30]. Therefore, we examined the response of
our regionally isolated microglia to the active metabolite
of MPTP, MPP+, to determine whether regionality
results in differential activation profiles. We found that
SN microglia (Fig. 2, left column) strongly upregulate
the expression of pro-inflammatory IL1β, IL12α, CCL3,
CCL4, and CCL19, while decreasing expression of antiinflammatory IFNγ in response to toxin treatment.
Interestingly, while there are some similarities in the
pro-inflammatory response of VTA microglia to MPP+
(Fig. 2, middle column), such as upregulation of IL1β,
CCL3, and CCL4, these microglia differ in their strong
downregulation of Cxcl12 and significant upregulation
of IL3. Finally, CTX microglia differ greatly from the
other two regions examined (Fig. 2, right column). Their
upregulation of pro-inflammatory cytokines is limited to
TNFα and RANTES, but with strongly decreased
expression of both IL1β and IL12α. However, CTX
microglia mimic SN in their downregulation of antiinflammatory IFNγ in response to MPP+ and also
decreased expression of IL6. The differential expression
of cytokines in response to MPP+ treatment would
suggest that the addition of regionally isolated microglia
would result in differential exacerbation of MPP+
toxicity of DA neurons.
Regionally isolated microglia similarly exacerbate
MPP+ toxicity

Due to the differences seen in the cytokine profile of
regionally isolated microglia, both at baseline and in
response to MPP+, we hypothesized that regionally
isolated microglia would cause differential exacerbation
of MPP+ toxicity of midbrain DA neurons grown with
their astrocytes. We find that compared to control
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Fig. 1 Regionally isolated microglia have distinct basal cytokine profiles. Microglia from the midbrain SN and VTA as well as the cortex (CTX) were
isolated based on previously established methods. We find that cultures of microglia are pure, and the vast majority (95–100%) of cells stain for
the microglial markers Iba1 (a) and CD11b (b). Regionally isolated microglia were subjected to qPCR analysis for 13 pro- and 8 anti-inflammatory
cytokines and compared between different regions. In comparison to CTX microglia, SN microglia (c), left column, exhibit greater expression of
the pro-inflammatory cytokines IL3, CCL3, and CCL4, with diminished IFNγ expression, whereas VTA microglia (c, right column) express greater
levels of RANTES, Cxcl12, and CCL19, while expressing lower levels of IL10. A secondary comparison against VTA microglia (d) demonstrated that
both SN (left column) and CTX (right column) microglia have greatly upregulated levels of IL10 and diminished expression of CCL19. A number
of other differences in these profiles demonstrate a regional variability to microglia

cultures (M = 100, SEM = 9.3), the addition of regionally
isolated microglia (SN light green, M = 105, SEM = 4.1;
VTA tan, M = 102, SEM = 3.1; and CTX light purple
bars, M = 105, SEM = 3.2) do not cause DA neuron
degeneration in either SN (Fig. 3a) or VTA (data not
shown, one-way ANOVA, F (7, 16) = 1.313 p = 0.3064)
neuron to astrocyte cultures. Interestingly, despite the
regionally associated expression differences of proinflammatory cytokines upon MPP+ stimulation, all
regionally isolated microglia similarly exacerbate MPP+
toxicity of SN DA neurons (Fig. 3a, SN dark green, M =
27, SEM = 1.5; VTA orange, M = 26, SEM = 2.1; and
CTX dark purple bars, M = 23, SEM = 1.8; one-way
ANOVA with Tukey’s post hoc multiple comparisons
test, F (7, 16) = 84.2, *** = p < 0.001), whereas VTA DA
neurons (data not shown) are robustly protected from
the effect of microglia in neuron to astrocyte cultures.
These results suggest that VTA, but not SN, astrocytes
may be protective of their regional DA neurons despite
the addition of damaging microglia regardless of their
region of origin.
Inhibition of microglial activation with a TLR4 antagonist
prevents exacerbation of MPP+ toxicity

To confirm that microglial released factors are indeed
responsible for the exacerbation of MPP+ toxicity, we
sought to prevent microglial activation by using a
recently developed, commercially available TLR4
antagonist TLR4-IN-C34 (C34) [31]. When C34 is
applied to cultures 2 h prior to MPP+ administration, we
found that C34 (Fig. 3b, light purple bar, M = 98, SEM =
1.7) itself has no effect on the health of mixed cultures
of SN neurons, astrocytes, and microglia (control, blue
bar, M = 96, SEM = 3.7). However, coupled with MPP+

treatment (Fig. 3b, dark purple, M = 56, SEM = 1.4), we
demonstrated significantly decreased exacerbation of
MPP+ toxicity (red bar, M = 35, SEM = 2.1) of SN DA
neurons (one-way ANOVA with Tukey’s post hoc multiple
comparisons test, F (3, 14) = 144.4, **** = p < 0.0001).
Cultures where C34 inhibition has occurred resemble our
previously established data where microglia are absent
from cultures (Kostuk et al. 2018, in submission). This
further supports that factors released from microglia
indeed exacerbate MPP+ toxicity of these neurons.
Isolated VTA, but not SN, astrocytes mediate protection
of both SN and VTA DA neurons from microglia

As we demonstrated that VTA neurons are robustly
protected from MPP+ toxicity despite the presence of
microglia, we sought to determine whether this
protection is due to astrocytic released factors. We
created both homo- and heterotypic astrocyte-neuron
cultures from the SN and VTA region in varying ratios
to determine if, similar to our previous findings, greater
numbers of astrocytes would afford protection despite
the presence of microglia. We found that in both
homotypic (SN DA neurons on SN astrocytes, Fig. 4,
solid blue bars: 1:2:1 ratio M = 37, SEM = 3.4; 1:4:1 ratio M = 34, SEM 1.5) and heterotypic (VTA DA neurons on SN astrocytes, Fig. 4, solid red bars: 1:2:1
ratio M = 45, SEM = 2.1; 1:4:1 ratio M = 41, SEM = 1.2)
co-cultures, higher ratios of SN astrocytes were incapable of affording greater protection of both SN and
VTA neurons when microglia were present at a ratio
equal to neurons. Conversely, VTA astrocytes exhibited ratio-dependent increases in protection of both
SN and VTA DA neurons despite the presence of
exacerbatory microglia in both homotypic (VTA DA
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neurons blue vertically stripped bar, M = 57, SEM = 0.
62 and VTA neurons red vertically stripped bar, M =
51, SEM = 1) by increasing the ratio of microglia
(one-way ANOVA with Tukey’s post hoc multiple
comparisons test; F (9, 28) = 270.8, ****p < 0.0001).
These results further suggest that microglial released
factors are able to overcome the protective effect of
astrocytes.

Fig. 2 Treatment of regionally isolated microglia with the Parkinson’s
toxin MPP+ causes differential upregulation of cytokines. Regionally
isolated microglia were collected and exposed to the PD toxin MPP+
for 24 h. After toxin exposure, microglia were examined for expression
of pro- and anti-inflammatory cytokines in comparison to untreated
region-specific controls. MPP+-treated SN microglia (left column)
exhibit a greater degree of pro-inflammatory cytokine upregulation,
including IL1β, IL12α, CCL3, CCL4, CCL19, IL1α, and TNFα, coupled with
significant downregulation of IFNγ compared to untreated control SN
microglia. VTA microglia (middle column) share upregulation of
pro-inflammatory IL1β, CCL3, CCL4, and TNFα similar to SN
microglia. However, they exhibit higher levels of IL3, as well as
the anti-inflammatory cytokines IL4, IL13, and IL6. Interestingly, CTX lack
upregulation of IL1β and IL12α, whereas they demonstrate strong
expression of TNFα

neurons on VTA astrocytes, Fig. 4, hatched red bars: 1:2:1
ratio M = 82, SEM = 1.2; 1:4:1 ratio M = 96, SEM = 0.75)
and heterotypic (SN DA neurons on VTA astrocytes,
Fig. 4, hatched blue bars: 1:2:1 ratio M = 86, SEM = 1.
2; 1:4:1 ratio M = 89, SEM = 1.8). To further our understanding of the protection provided by VTA astrocytes, we then sought to tip the balance towards the
deleterious effects of microglia by increasing their
proportion of the cells in the dish. We found that the
addition of microglia at a 2:1 ratio to neurons in the
presence of the most protective astrocyte ratio (4:1
astrocytes to neurons) does result in DA neuron
death simply because more microglia were added
(data not shown). However, when coupled with MPP+
treatment, we found that the protective effect of VTA
astrocytes was significantly diminished (Fig. 4; SN

Discussion
The regional vulnerability of SN DA neurons has been
extensively studied for a number of years, with many
studies focusing on the intrinsic underlying mechanisms
and how these neurons differ from neighboring VTA
neurons [2–5]. Recently, however, greater emphasis has
been placed on understanding potential non-cell autonomous mechanisms, such as the impact of microglial
cells, which may underlie this selective vulnerability.
In this study, we demonstrate that regionally isolated
microglia of midbrain SN and VTA subregions differ in
both their basal and MPP+-induced cytokine profiles.
Furthermore, we demonstrate that the addition of
regionally isolated microglia themselves is not deleterious
to DA neurons; however, their presence significantly
exacerbates MPP+ toxicity in SN DA neurons. Conversely,
VTA DA neurons co-cultured with astrocytes are robustly
protected from MPP+ toxicity despite the presence of
microglia, suggesting that VTA astrocytes may be
responsible for protection of these neurons. We further
showed that pharmacological inhibition of microglial
activation diminished the exacerbatory effect of microglia.
Finally, we demonstrated that VTA astrocytes, but not
SN, are able to protect both SN and VTA DA neurons
from MPP+ toxicity despite the presence of deleterious
microglia but that it is possible to overburden protective
astrocytes with increasing numbers of microglia, thus
increasing the presumptive load of microglial released
factors.
The role of microglia as the immune cells of the CNS
has been appreciated for a number of years [6]. Many
studies have demonstrated an increased release of proinflammatory/neurotoxic species from microglia in
response to inflammatory stimuli such as LPS [18].
Additionally, some studies have postulated a role for
microglia in the progression of PD [11, 32, 33], though a
debate continues as to whether microglia play a role in
initiation of disease or are activated secondary to neuronal death. Supporting the latter proposition, there are a
number of reports demonstrating a response of microglia to some PD toxins. Gao et al. [24] showed that the
effect of rotenone, a pesticide that has been used as a
PD mimetic toxin in culture, requires the presence of
microglia and that this effect is dependent on the number of microglia present within the culture. Additionally,
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Fig. 3 Toxicity of SN DA neurons by MPP+ is exacerbated in the presence of regional microglia and is alleviated by inhibition of microglial
activation. a The addition of regionally isolated microglia (SN, VTA, CTX) to cultures of SN DA neurons and astrocytes demonstrates that the
addition of microglia themselves is not deleterious to these neurons. However, coupled with MPP+ treatment, all regionally isolated microglia
cause exacerbation of toxicity to a similar extent; one-way ANOVA with Bonferroni’s post hoc multiple comparisons test; F (7, 16) = 84.2,
****p < 0.0001. b TLR4 inhibitor C34 (light purple) does not cause any degeneration of SN DA neurons in culture. However, a significant decrease
in the exacerbation of MPP+ toxicity is observed when microglial activation is inhibited by the drug (red compared to purple); one-way ANOVA
with Tukey’s post hoc multiple comparison test; F (3, 14) = 144.4, ****p < 0.0001

Chien et al. [34] demonstrated that microglial released
cytokines and chemokines are responsible for the loss of
nigrostriatal DA neurons in response to LPS. Furthermore, recent work by Smeyne et al. [16] demonstrated
that systemic injection of the PD mimetic toxin MPTP
results in increased microglial reactivity within the SN,
suggesting that PD mimetic toxins can directly cause
microglial activation and subsequent cytokine release.
These findings are similar to ours in which microglial
addition to DA neuron cultures exacerbates the effect of
the PD mimetic toxin MPP+, suggesting that the release
of pro-inflammatory molecules from microglia may have
a vital role in the progression of PD DA neuron
degeneration.

Previous studies have also demonstrated that the inhibition of microglial activation or knockdown of released cytokines from microglia may be neuroprotective
to DA neurons. Pharmacological blockade of microglial
activation [35–37] or knockdown of cytokines, such as
IL-1 [38], demonstrates that prevention of microglial
activation attenuates some of the degeneration seen in
models of PD. Furthermore, the interaction of MPTP/
MPP+ with the microglial receptor TLR4, a key receptor
in the microglial activation pathway, has previously been
established [39, 40]. As such, it is unsurprising that our
findings demonstrate that the use of a new TLR4
inhibitor C34 [31], prior to MPP+ administration, results
in decreased exacerbation of toxicity.

Kostuk et al. Journal of Neuroinflammation (2018) 15:139

Page 8 of 11

Fig. 4 Greater ratios of isolated VTA, but not SN, astrocytes protect both SN and VTA DA neurons from MPP+ toxicity in the presence of
microglia, but increased numbers of microglia counter this protection. Regionally homo- and heterotypic cultures were established with SN and
VTA neurons/astrocytes. Greater ratios of SN astrocytes fail to increase SN (solid blue bars) or VTA (solid red bars) DA neuron survival in the
presence of microglia. Conversely, VTA astrocytes robustly protect both SN (blue hatched bars) and VTA (red hatched bars) DA neurons from
exacerbation of MPP+ toxicity when microglia are present. The protective effect of VTA astrocytes on SN (blue vertical striped bar) and VTA
(red vertical striped bar) neurons is diminished when the ratio of microglia to neurons is increased from 1:1 to 2:1. Data are presented as
mean ± SEM; one-way ANOVA with Tukey’s post hoc multiple comparison test; F (9, 28) = 270.8, ****p < 0.0001

In addition to an effect of the PD mimetic toxins
MPTP or MPP+ on the activation of microglia, a
number of studies have examined the impact of alpha
synuclein (α-syn) on microglia and the subsequent
activation of these cells [33, 41–43]. Indeed, studies have
demonstrated that α-syn is able to bind to surface receptors of microglia and result in their activation and
subsequent upregulation of pro-inflammatory cytokines [44–46]. Therefore, it is plausible that the interaction of α-syn and microglia of the midbrain may be
exacerbating or contributing to DA neuronal degeneration similar to that seen by the effect of MPP+ in
our studies. However, it is still relatively unknown
whether this interaction of α-syn and microglia is an
initiating factor for neuronal death or secondary to
the release of species from damaged or dying neurons
[43]. Furthermore, a number of studies have demonstrated that microglia can act as scavengers of extracellular α-syn [47, 48], thereby clearing a potentially
damaging species away from vulnerable neurons. The impact of microglial-sequestered α-syn is not fully understood, and it is possible that internalized α-syn could
result in dysfunction of lysosomal pathways within microglia, similar to that seen in DA neurons [49], impairing
normal functions within these cells. Therefore, the effect
that α-syn may have on microglia from the SN and VTA
remains an important area of investigation.

The regional variability in the transcriptional profile of
microglia has been investigated previously [27]. However, potential differences of microglia within the midbrain have yet to be investigated. Our study is the first
of our knowledge to sub-dissect the midbrain into the
vulnerable SN and protected VTA to examine the effects
of isolated microglia of these regions in a PD model.
Though we demonstrate a number of basal and MPP+induced cytokine differences, it is interesting to note
that we fail to find any regionally specific exacerbation
of MPP+ toxicity. A number of possible explanations
exist for this fact.
First, our investigation of the transcriptional profile of
these microglia was somewhat limited. We established a
list of 21 canonical pro- and anti-inflammatory cytokines
based on commercially available arrays. This is a very
limited view of the transcriptional profile of these cells. As
such, future studies utilizing more in-depth methods of investigation, such as RNAseq, are required. These methods
have been used in other models, such as spinal cord injury
[50], and have demonstrated a vast array of subtle injuryinduced changes to microglia that should likewise be
appreciated in the context of the midbrain in PD.
Secondly, the deleterious effect of these regionally
isolated microglia could simply be due to a combined
CCL3, CCL4, and TNFα response, as these are the three
pro-inflammatory cytokines upregulated in all three
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regionally isolated microglial populations. However, the
role of these cytokines has been investigated extensively
in the context of PD [51–53], though the specific action
of SN or VTA microglial-derived cytokines is still
unknown. A possible course of investigation would be to
selectively inhibit the production of these cytokines, or
their downstream pathways, directly within these
distinct midbrain nuclei and examine their effects in an
in vivo PD model.
Finally, the response of microglia to inflammatory stimuli, such as LPS, is understood to be temporally dynamic.
Indeed, previous studies have demonstrated that changes
in the expression level of known pro-inflammatory cytokines can change even within 4 h of stimulus initiation,
and these changes can be transient and disappear by 24 h
after stimulus [54, 55]. Our examination of expression
levels of cytokines was limited to the 24-h time point, as
this is when we typically see the greatest death of DA neurons after MPP+ treatment. However, we cannot rule out
the effect of earlier cytokine responses and their impact
on DA neuronal survival. Further RNAseq studies
examining the temporal gene expression changes of
isolated SN, VTA, and CTX microglia are required to fully
understand the role these cells may have in the initiation
or exacerbation of DA neuronal death in response to
MPP+.
The role of astrocytes as neuroprotective cells has
been well established for a number of years [56–58]. Indeed, our recent work (Kostuk et al. 2018, in submission)
has demonstrated a vast transcriptional difference between the astrocytes of the SN and VTA, suggesting that
VTA astrocytes are able to mediate protection of their
regional DA neurons whereas SN astrocytes lack this
ability. Furthermore, the crosstalk between astrocytes,
neurons, and microglia has recently become more appreciated [59–61]. Thus, the interaction of midbrain astrocytes and microglia in the context of PD pathogenesis
is an important avenue of investigation. Consequently, it
is unsurprising to us that greater ratios of SN astrocytes
fail to mediate greater protection when deleterious microglia are present and that VTA astrocytes robustly protect
both SN and VTA DA neurons from MPP+ toxicity
despite the presence of microglia. Interestingly, however,
we were able to demonstrate that it is possible to
overburden protective astrocytes with greater numbers of
microglia by increasing the ratio of microglia to neurons
and likely their released cytokines in our cultures. This is
of vital importance, as SN microglial activation and
proliferation is a key feature of both human PD
pathogenesis [15, 62] and animal models [16] of the
disease. Therefore, as the concentration of microglial
factors increases during the course of disease, less
protective astrocytes in the SN may become more
overtaxed by significant increases of microglial-released
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cytokines. In contrast, VTA astrocytes may be better
suited to balance against these deleterious factors as there
are fewer microglia and greater proportions of protective
astrocytes present basally [25, 26, 63, 64], and thus, microglial activation or proliferation may never reach the critical
threshold needed to cause VTA DA degeneration.

Conclusions
In summary, the data in this paper suggests that regional
differences in vulnerability of midbrain DA neurons to the
PD toxin MPP+ may rely on a delicate balance between
protective factors supplied by astrocytes and deleterious
cytokines released by microglia. We demonstrate that
regionally isolated microglia of the SN, VTA, and CTX
differ in their basal and MPP+-induced cytokine profiles.
Despite these transcriptional differences, all regionally
isolated microglia exacerbate MPP+ toxicity of SN DA
neurons, and this exacerbation can be attenuated by
inhibition of microglia activation. Furthermore, VTA, but
not SN, astrocytes are able to mediate protection from
microglial-released factors, though it is possible to overcome the protective function of astrocytes with greater
numbers of microglia. Thus, these findings help to expand
our current view of this neurodegenerative disease process
and highlight the need for greater understanding of the
balanced role of astrocytes and microglia in the midbrain.
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